問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

更新時間：2023-09-19

鄭景泉ZHENG, JING-QUAN
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 7 years 10 個月

Recruiting Trial

43Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鄭景泉

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

List

23Cases

2025-09-01 - 2035-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    Tablets Subcutaneous Injections

Participate Sites
6Sites

Recruiting6Sites

2023-04-17 - 2026-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-09-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

2020-11-01 - 2026-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2020-06-01 - 2029-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-12-01 - 2032-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-10-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2022-01-01 - 2031-02-27

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2020-09-15 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting6Sites

Terminated6Sites

2023-07-07 - 2026-07-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB